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In an effort to identify target genes in acute myeloid leukemia (AML), wecompared gene expression profiles between normal and AML cells fromvarious publicly available datasets. We identified CD99, a gene that is
up-regulated in AML patients. In 186 patients from The Cancer Genome
Atlas AML dataset, CD99 was over-expressed in patients with FLT3-ITD
and was down-regulated in patients with TP53mutations. CD99 is a trans-
membrane protein expressed on leukocytes and plays a role in cell adhe-
sion, trans-endothelial migration, and T-cell differentiation. The CD99 gene
encodes two isoforms with distinct expression and functional profiles in
both normal and malignant tissues. Here we report that, although the
CD99 long isoform initially induces an increase in cell proliferation, it also
induces higher levels of reactive oxygen species, DNA damage, apoptosis
and a subsequent decrease in cell viability. In several leukemia murine mod-
els, the CD99 long isoform delayed disease progression and resulted in
lower leukemia engraftment in the bone marrow. Furthermore, the CD99
monoclonal antibody reduced cell viability, colony formation, and cell
migration, and induced cell differentiation and apoptosis in leukemia cell
lines and primary blasts. Mechanistically, CD99 long isoform resulted in
transient induction followed by a dramatic decrease in both ERK and SRC
phosphorylation. Altogether, our study provides new insights into the role
of CD99 isoforms in AML that could potentially be relevant for the preclin-
ical development of CD99 targeted therapy.
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ABSTRACT
Introduction
The outcome of patients with acute myeloid leukemia (AML) remains dismal
due to the high relapse rate.1 To identify target genes that were differentially over-
expressed in AML compared with normal hematopoietic cells, we leveraged
genomic and transcriptomic data and discovered CD99.
CD99, a membrane glycoprotein,2 is normally expressed in cortical thymocytes,
mature plasma cells, granulosa cells of the ovary, Sertoli cells of the testis, and pan-
creatic islet cells.3 The CD99 gene encodes two distinct proteins that are produced
by alternative splicing of the CD99 transcript. The alternative spliced short isoform
results from a deletion in its intracytoplasmic fragment.2 CD99 plays a role in cell
migration,4 adhesion, differentiation of thymocytes and T cells,2 and regulation of
diapedesis.5 In cancer cells, CD99 is highly expressed on the cell surface of Ewing's
sarcoma (EWS),6 gliomas7 and other mesenchymal,8,9 hematopoietic,10-12 and epithe-
lial cancers.13,14 In EWS, engagement with the anti-CD99 antibody enhanced apop-
tosis and sensitivity to chemotherapy.15 High CD99 correlated with enhanced inva-
sion of glioma cells.7
CD99 immunoreactivity was found in AML but rarely
in myeloproliferative disorders, myelodysplastic syn-
dromes, remission, and normal marrow samples.16 A
recent study, however, showed that CD99 is a disease
stem cell marker, and CD99 antibody proved beneficial in
xenograft mice models of myeloid malignancies.17 With
growing evidence that CD99 plays a role in cancer, and
particularly in AML, and that CD99 isoforms are differen-
tially expressed and play different roles in different
hematopoietic cells,18 investigating the roles of the two
isoforms is crucial for CD99 preclinical development as a
therapeutic target. Here we characterize CD99 upregula-
tion in patients with AML and its association with clinical
and molecular characteristics, and determine the function




Diagnostic or relapse blood was obtained from AML patients
treated at the Norris Comprehensive Cancer Center at the
University of Southern California (USC) after obtaining written
informed consent. The use of human materials was approved by
the Institutional Review Boards of the USC in accordance with the
Declaration of Helsinki. 
Patient datasets and gene expression analysis
The Cancer Genome Atlas (TCGA) AML dataset was down-
loaded from oncomine.19,20 Patients data from the GSE7186,21
GSE13159,22 GSE1159,23 GSE15434,24 GSE3077,25 GSE425,26
GSE12417,27 and GSE1785528 datasets were downloaded from the
GEO database. Details of analysis methods are available in the
Online Supplementary Appendix.
Cell lines and primary blasts
Acute myeloid leukemia cell lines were grown in Roswell Park
Memorial Institute (RPMI) medium supplemented with 10% fetal
bovine serum (FBS) and 100U/mL penicillin. Peripheral blood
mononuclear cells (PBMC) from AML patients and from healthy
donors were isolated by density gradient centrifugation using
Ficoll-Paque. Primary cells were grown in RPMI plus 20% FBS and
cytokine cocktails CC100 (Flt3L, SCF, IL-3 and IL-6). 
In vivo studies 
Animal protocols were approved by the Institution for Animal
Care and Use Committee (IACUC) of the USC. For THP-1 and
MOLM-13 xenograft experiments, 2.5x106 cells were injected via
tail-vein (IV) into 4-6 week-old NOD-scid /Il2rg-/- (NSG) mice
(Jackson). For the primary blasts xenograft experiment, 1x106 cells
were IV engrafted into irradiated mice. Details of the methods
used, including plasmids, primer sequences, antibodies and in vivo
experiments are available in the Online Supplementary Appendix.  
Results
CD99 is up-regulated in acute myeloid leukemia
In an effort to identify target genes that were differen-
tially over-expressed in AML, we compared gene expres-
sion profiles between normal and AML cells from various
available public datasets. We found that CD99 was signif-
icantly up-regulated in AML compared with normal cells
in five datasets with available measurements of CD99
RNA levels in both leukemia and normal cells (oncomine
median ranking among up-regulated measured genes 155,
P=0.013; TCGA data did not have CD99 levels in normal
cells). CD99 was significantly higher in 23 AML samples
compared with six normal bone marrow (BM) samples
(GSE7186: 3.5-fold, P<0.0001) (Figure 1A). Consistently,
CD99 was significantly over-expressed in blasts of 542
patients with AML compared with PBMC from 74
healthy donors (HD) (GSE13159: 2-fold, P<0.0001) (Figure
1B). Similarly, CD99 expression was 1.8-fold higher in
blasts from 285 patients with AML compared with HD
cells (GSE1159: P=0.003) (Online Supplementary Figure
S1A). There was a 2.3-fold increase in CD99 expression
(GSE13164: P<0.001) (Online Supplementary Figure S1B) in
blasts of 257 AML patients compared with PBMC of 58
HD. In the GSE995 dataset, CD99 expression was 3-fold
higher in blasts from nine AML patients compared with
that in cells from six HD (P=0.028) (Online Supplementary
Figure S1C). We also analyzed the expression of CD99
protein coding transcripts in patients with AML
(GSE106291; n=246). ENST00000381192.10 (CD99-L) and
ENST00000611428.5 (CD99-S) were the top expressed
transcripts (Figure 1C). The combined expression of
ENST00000482405.7 and ENST00000611428.5 (both code
for CD99-S) was significantly higher (P=0.0073) than the
level of ENST00000381192.10 (CD99-L) (Online
Supplementary Figure S1D). Transcript Ensembl IDs are
described in Online Supplementary Table S1. The transcript
expression of the two isoforms were positively correlated
(Online Supplementary Figure S1E and F).
Several reports suggested that CD99 is up-regulated on
leukemia stem cells.29-31 To validate this, we assessed CD99
expression in the GSE3077 dataset that has gene expres-
sion data of leukemia blasts obtained from 23 patients
with AML sorted according to their CD34 and CD38
expression levels. We found that CD99 expression was
significantly higher (1.34-fold, P<0.001) (Figure 1D) in the
CD34+CD38+ and CD34+CD38- combined subpopulation
compared with CD34-CD38- and CD34-CD38+ combined.
CD99 overexpression is positively associated with 
FLT3-ITD and reversely with TP53 mutations
We assessed the association between CD99 upregula-
tion and the presence of AML mutations. In the TCGA
dataset, CD99 expression was significantly higher
(P=0.004) in patients with FLT3-ITD (n=37) compared
with patients with FLT3 point mutations (n=16) and FLT3
wild-type (n=133) (1.3 fold, P=0.002) (Figure 1E). Similarly,
there was a significant association between high CD99
(above the median) and the presence of FLT3-ITD muta-
tion (Fisher's exact test, P=0.04) (Online Supplementary
Table S2). A similar association was found in the
GSE17855 and GSE15434 datasets with childhood AML
and patients with cytogenetically normal karyotype,
respectively. CD99 is significantly higher in patients with
FLT3-ITD compared with patients with FLT3 wild-type
(FLT3-WT) (1.3-fold, P=0.03, Online Supplementary Figure
S1G; 1.4-fold, P<0.001, Online Supplementary Figure S1H;
respectively). We next examined the association of each
CD99 transcript with FLT3-ITD mutation.
ENST00000381187.8 and ENST00000624481.4 were sig-
nificantly higher in FLT3-ITD compared with FLT3-WT
patients (P=0.001 and P=0.002) (Online Supplementary
Figure S1I-N). ENST00000611428.5 (CD99-S) was not sig-
nificantly associated with FLT3-ITD after adjusting for
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multiple hypotheses testing (unadjusted P=0.049).
CD99 expression was significantly lower (1.9-fold,
P<0.001) in patients with mutated TP53 (n=15) compared
with patients with TP53-WT (n=171) (Online
Supplementary Figure S1O; Fisher's Exact test, P=0.0006,
Online Supplementary Table S1). CD99 expression was not
associated with other mutations (Online Supplementary
Table S2 and Online Supplementary Figure S2).
CD99 expression levels according to patients’ clinical
characteristics
We dichotomized patients into high and low groups
based on CD99 median expression. Patients with CD99-
low had a significantly lower percentage of bone marrow
(BM) blasts (median, 66.2 vs. 72.5, P=0.024), peripheral
blood (PB) blasts (median, 23.7 vs. 50.7, P<0.0001), and
white blood cell (WBC) count (median, 27.7 vs. 45.8,
P=0.019). The median age was 57.8 years in CD99-low
and 52.1 years in CD99-high groups (Online Supplementary
Table S3). 
According to the National Comprehensive Cancer
Network (NCCN), AML is classified into favorable, inter-
mediate and poor-risk groups based on patients molecular
and cytogenetic characteristics. CD99 expression was sig-
nificantly higher in the favorable-risk group than that in
the intermediate-risk  (1.2-fold, P<0.01) and poor-risk  (2-
fold, P<0.0001) groups (Figure 2A). According to the AML
French-American-British (FAB) classification data, patients
with M5-AML had lower CD99 expression compared
with M1, M2, M3 and M4 (Online Supplementary Figure
CD99 overexpression in AML




Figure 1. Characterization of CD99 expression in acute myeloid leukemia
(AML) datasets. (A) Relative expression of CD99 in 23 AML cases compared
with six healthy donors in the GSE7186 dataset. (B) Relative expression of CD99
in 542 AML cases compared with 74 healthy donors in the GSE13159 dataset.
(C) Characterization of CD99 transcript expression in 246 patients with AML
from the GSE106291 dataset. (D) 23 human tissue samples obtained from
GSE30377 dataset were sorted into CD34+CD38-, CD34+CD38+, CD34-CD38-
and CD34-CD38+ and analyzed for CD99 expression. (E) Relative expression of
CD99 in 37 patients with FLT3-ITD compared with that in 149 patients without
FLT3-ITD (WT) in the TCGA dataset. N: number (**** P<0.0001; *** P<0.001;
** P<0.01; *P<0.05).
S3A). Based on leukemia cytogenetics, no significant dif-
ferences in CD99 expression was found in patients with
complex karyotype, Inv (16), t (15; 17), t (8,21), del (7q) /
7q- and trisomy 8, compared with normal karyotype
(Online Supplementary Figure S3B). 
CD99 overexpression is associated with better clinical
outcome
The overall survival (OS) of CD99-high patients (based
on median cut-off) was significantly longer than that of
CD99-low patients (median: 27 vs. 11.2 months;
P=0.0026) (Figure 2B). Patients with t(15;17) are treated
with all-trans retinoic acid (ATRA) and have a better out-
come, thus they were excluded from the survival analyses.
When patients were stratified into cytogenetically normal
(CN) and cytogenetically abnormal (CA), we found that in
CA-AML, but not in CN-AML, CD99-high survived sig-
nificantly longer than CD99-low patients (CA-AML:
median OS: 32.3 vs. 11 months, P=0.02, Figure 2C; CN-
AML: P=0.24, Online Supplementary Figure S4A). Yet, there
was no significant difference in CD99 levels between CN-
AML and CA-AML (P=0.33) (Online Supplementary Figure
S4B). There was no significant difference in event-free sur-
vival (EFS) between CD99-high and CD99-low patients
(median: 15.6 vs. 13.3 months; P=0.13) (Online
Supplementary Figure S4C-E).
In the GSE425 dataset of 71 patients with CA-AML,
CD99-high patients survived significantly longer than
CD99-low patients (P=0.04) (Online Supplementary Figure
S5B). No significant difference in OS was found when we
included CN-AML patients or analyzed them separately
(Online Supplementary Figure S5A and C). In the GSE12417
dataset, which includes only CN-AML patients, no signif-
icant difference between CD99-high and CD99-low
patients (n=163) was observed (Online Supplementary
Figure S5D). 
In a multivariable analysis, high CD99 was not signifi-
cantly associated with OS when adjusted by age, cytoge-
netic risk, transplant status, DNMT3A mutation status,
and TP53 mutation status (P=0.364) (Online Supplementary
Table S4).
We also assessed the association of CD99 transcript
upregulation with OS in 246 patients with AML using
median cut-off for each transcript. High
ENST00000381192.10 (CD99-L) exhibited a trend of asso-
ciation with better OS (GSE106291: median OS: 908 vs.
445 days; P=0.06) (Figure 2D). No difference in survival
between high and low expression was observed for the
other transcripts (Online Supplementary Figure S6A-G).
Differential effect of CD99 isoform expression 
on leukemia growth
In a panel of AML cell lines (KG-1, KG-1A, MOLM13,
MV4-11, Kasumi-1, THP-1, NB4, U937, UOC-M1), CD99
surface levels are higher than that of healthy cord blood
cells (Figure 3A). Western blots revealed 28 and 32kDa
bands corresponding to CD99-L and -S in U937, KG-1A
and Kasumi-1 cells, but only the lower band was recog-
nized in THP-1, MOLM-13, CD34+ cells and two HD
PBMC lysates (Figure 3B and Online Supplementary Figure
V.P. Vaikari et al.
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Figure 2. Association of CD99 expression with patients’ clinical characteristics in acute myeloid leukemia (AML) datasets. (A) Relative expression of CD99 according
to the National Comprehensive Cancer Network (NCCN) risk status classification in the The Cancer Genome Atlas (TCGA) dataset. (B) Overall survival (OS) of 173
patients grouped based on CD99 median expression into CD99 high (n=87) and CD99 low (n=86) from the TCGA dataset. (C) OS of cytogenetically abnormal (CA-
AML) cases grouped based on CD99 median expression into CD99 high (n=42) and CD99 low (n=42). (D) OS of 146 patients grouped based on




S7A). Similarly, quantitative polymerase chain reaction
(qPCR) analysis showed that CD99 transcripts were up-
regulated in AML blast samples (n=9) and AML cell lines
(KG-1a, U937, THP-1, and MOLM-13) compared with
HD PBMC (n=3) and CD34+ cells. Transcript
ENST00000482405.7 is higher in CD34+ cells than in AML
cell lines (Online Supplementary Figure S7B; for qPCR
primers see Online Supplementary Table S5).
CD99 overexpression in AML
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Figure 3. Effect of CD99 isoform expression on acute myeloid leukemia (AML) cell proliferation. (A) Relative CD99 expression in cord blood cells (n=2) and AML cell
lines (n=9) measured by flow cytometry. (B) Western blot analysis of CD99 isoform expression in CD34+ cells, healthy donor peripheral blood mononuclear cells
(PBMC) and AML cell lines. (C) Viability of CD99-shRNA knockdown in THP-1, MOLM-13, U937 and AML-4 cells measured 96 hours (h) after transfection using try-
pan-blue and alamar-blue. (D) Quantative polymerase chain reaction (qPCR) analysis using CD99 TaqMan assay to confirm CD99 knockdown in THP-1, MOLM-13,
U937 and AML-4 cells transfected with CD99-shRNA plasmid (or EV) for 96 h. CD99 expression was normalized to EV cells. (E) CD99 expression in EV, CD99-L OE
and CD99-S OE cells measured by flow cytometry in THP-1, U937 and MOLM-13 cells.(F) Proliferation assay of EV, CD99-L and CD99-S measured at 24,48 and 72
h by trypan-blue (n=4) in THP-1, U937, and MOLM-13 cells. Data reported as number of live cells. (G) Viability of AML blasts over-expressing CD99-L or EV measured
96 h after lentiviral transduction using trypan-blue (n=7). Data reported as total number of live cells/mL. (H) Viability of AML blasts over-expressing CD99 L, CD99-
S or EV measured 96 h after lentiviral transduction using trypan-blue (n=3). Data reported as the number of live cells/mL. (I) Long-term proliferation assay of EV,








We then examined the effect of CD99 knockdown on
cell viability. Transducing cells with lentiviral-CD99-
shRNA significantly reduced primary AML blast viability
(n=4) (Figure 3C and Online Supplementary Figure S7C) and
AML cell lines (THP-1, MOLM-13, and U937) (40-60%;
P<0.05) (Figure 3C). Knockdown was confirmed by qPCR
(Figure 3D) and western blot (Online Supplementary Figure
S7D). THP-1 and MV4-11 cells had an approximately 35-
50% decrease in cell viability when transiently transfected
by elecroporation with CD99-siRNA compared with neg-
ative-control-siRNA (P=0.001 and P=0.001, respectively)
(Online Supplementary Figure S7E-G). 
We also established a gain-of-function approach to
study CD99-L and CD99-S isoform functions. We per-
formed lentiviral transduction to over-express CD99-L and
CD99-S in THP-1, U937 and MOLM-13 cells expressing
variable endogenous levels of CD99 isoforms (Figure 3E
and Online Supplementary Figure S7H and I). CD99-L trans-
duced cells had increased cell proliferation at 72 hours (h)
compared with their respective empty vector (EV) controls
and CD99-S transduced cells, respectively, counted by try-
pan-blue in THP-1 (1.78-fold, P<0.001; 1.61-fold, P<0.01),
U937 (1.47-fold, P<0.001; 2.59-fold, P<0.0001), and
MOLM-13 cells (2-fold, P<0.0001; 1.45-fold, P<0.0001)
(Figure 3F). This was also confirmed by alamar-blue assay
(Online Supplementary Figure S8A) and by BrdU staining
(1.6-fold, P=0.006) (Online Supplementary Figure S8B) sug-
gesting enhanced metabolic activity and DNA synthesis in
these cells, respectively. 
We also ectopically over-expressed CD99-L in AML
blasts (n=7) (Online Supplementary Table S6) using lentiviral
transduction. Overexpression of CD99-L was confirmed
using western blot and fluorescence microscopy for green
fluorescent protein (GFP) (Online Supplementary Figure S8C
and D). Higher cell number was observed in lenti-CD99
blasts compared with lenti-EV transduced blasts 96 h after
viral transduction (2.8-fold, P<0.0001) (Figure 3G). We also
observed a modest increase in the number of colonies on
day 14 in 3 of 6 patient samples over-expressing CD99-L
compared with their respective controls: AML-3 (6 vs. 15,
P=0.02), AML-4 (6 vs. 14, P=0.02), and AML-5 (42 vs. 128,
P=0.001) (Online Supplementary Figure S8E). Furthermore,
we ectopically expressed CD99-L and CD99-S in three
additional AML blast samples (Online Supplementary Figure
S8F). Cell viability was measured 96 h after transduction
using trypan-blue and alamar-blue. A higher number of
live cells was observed in CD99-L transduced blasts com-
pared with lenti-EV (1.5-fold, P<0.0001) and CD99-S
transduced blasts (1.3-fold, P<0.0001) (Figure 3H). More
colonies were observed in one sample over-expressing
CD99-L compared with their respective controls; AML-10
(49.5 vs. 101.5, P=0.04) (Online Supplementary Figure S8G). 
However, long-term culture of CD99-L transduced cells
showed a subsequent drop in cell viability, and cells could
not be maintained in culture for more than 4-6 weeks. To
validate this, we performed a long-term culture assay for
ten days starting approximately two weeks post viral
transduction. Proliferation of CD99-L cells started to
decline by day 5 of initial serum stimulation compared
with EV and CD99-S cells, even when cell density and
nutrients were accounted for (Figure 3I). In CD34+ cells,
we observed no significant change in the number of viable
cells between cells transduced with CD99-L, -S isoform or
EV (Online Supplementary Figure S8H) at 96 h post trans-
duction. Transducing cells with lentiviral-CD99-shRNA
resulted in a slight decrease in cell viability (Online
Supplementary Figure S8I).  
Ectopic expression of CD99 long isoform enhances
reactive oxygen species levels, DNA damage, and
induces cell apoptosis 
Because the initial enhanced proliferation of CD99-L
cells was serum induced and reversed with further expan-
sion in vitro, we speculated that the serum-induced cell
growth would stimulate higher production of reactive
oxygen species (ROS) in these cells. Indeed, THP-1 cells
transduced with CD99-L exhibit a 2.5- and 1.6-fold
increase in ROS levels compared with CD99-S and EV
cells, respectively (Figure 4A and B). Because of their high-
er ROS levels, we asked whether DNA damage is
increased in these cells. Western blot analysis showed that
CD99-L cells exhibit a higher level of the DNA damage
marker H2Axg compared with CD99-S and EV cells
(Figure 4C). Furthermore, apoptosis was also enhanced in
CD99-L transduced cells measured by annexin-V staining
in THP-1 (CD99-L vs. EV: 3.48-fold, P=0.001; CD99-L vs.
CD99-S: 6.32-fold, P=0.0027), U937(CD99-L vs. EV: 3.26-
fold, P=0.07; CD99-L vs. CD99-S: 3.67-fold, P=0.10), and
MOLM-13 cells (CD99-L vs. EV: 4.88-fold, P=0.0032;
CD99-L vs. CD99-S: 4.2-fold, P=0.0042) (Figure 4D and E).
The enhanced apoptosis was also confirmed by the
increase of cleaved caspase-3 (Figure 4F).   
Ectopic expression of CD99-L isoform induces myeloid
differentiation and reduces cell migration
Previous studies have demonstrated that CD99 homo-
typic interaction in CD99 expressing cells32-34 plays a role in
monocyte trans-endothelial migration.4 Thus, we asked
which isoform is responsible for cell homotypic interac-
tion, and whether they affect cell migration and myeloid
differentiation differently. Cells were seeded at
1x105cells/mL per well in a 6-well-plate and images were
taken 6 h later; CD99-L THP-1 cells displayed higher cell
aggregation compared with EV and CD99-S cells (Figure
5A). CD99-L cells exhibit decreased migration towards
SDF-1α in a transwell chamber compared with EV and
CD99-S cells; THP-1 (70%, P<0.0001; 66%, P<0.0001),
U937 (80%, P<0.0001; 83%, P<0.0001), and MOLM-13
(80%, P<0.0001; P=0.0032) (Figure 5B and C).  
CD99-L expressing cells showed an increase in CD11b
surface marker measured by flow cytometry 24 h after
cells were seeded in THP-1 (CD99-L vs. EV: 2-fold,
P=0.0027; CD99-L vs. CD99-S: 1.63-fold, P=0.043), U937
(CD99-L vs. EV: 1.56-fold, P=0.01; CD99-L vs. CD99-S:
1.29-fold, P=0.11), and MOLM-13 (CD99-L vs. EV: 1.89-
fold, P<0.0001; CD99-L vs. CD99-S: 1.68-fold, P<0.079)
(Figure 5D). 
Ectopic expression of CD99 long isoform delayed
leukemia engraftment in acute myeloid leukemia
murine models
Next, we investigated the effect of ectopic expression of
CD99 isoforms in murine leukemia models. THP-1 cells
stably over-expressing CD99-L (n=6), CD99-S (n=3), or EV
(n=6) were injected into NSG mice. Mice were sacrificed on
day 30-32 post implantation. Mice engrafted with CD99-L
cells had smaller spleens compared with EV mice (0.04g vs.
0.07g, P=0.010) and CD99-S mice (0.04g vs. 0.06g,
P=0.0003) (Figure 6A and B). hCD45 flow analysis revealed
that CD99-L mice had significantly less BM engraftment
V.P. Vaikari et al.
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Figure 4. Effect of ectopic expression of CD99 long isoform on reactive oxygen species (ROS) lev-
els, DNA damage and cell apoptosis. (A and B) ROS levels of EV, CD99-L and CD99-S cells deter-
mine by flow cytometry using the cell ROX reagent in THP-1 cells (n=4) measured by flow cytome-
try. (C) Western blot analysis of H2Axg in THP-1 EV, CD99-L and CD99-S. (D and E) Apoptosis analy-
sis of EV, CD99-L and CD99-S cells determined by annexin V+ cells through flow cytometry in THP-
1, U937 and MOLM-13 cells (n=4). (F) Western blot analysis of cleaved caspase-3 in THP-1 EV,






compared with EV (7.29% vs. 19.47%; P=0.02) and CD99-
S mice (7.29% vs. 18.9%; P=0.04) (Figure 6C). CD99-L mice
had significantly less PB engraftment compared with EV
(14.73% vs. 84.52 %; P=0.0002) and CD99-S mice (14.73%
vs. 83.3 %; P=0.006) (Figure 6D and Online Supplementary
Figure S9). No difference in engraftment was seen in the
liver (Online Supplementary Figure S10A) or  spleen (Online
Supplementary Figure S10B) between groups. 
In the MOLM-13 murine model, mice were engrafted
with CD99-L, CD99-S and EV mice (n=6 for EV and CD99-
L, and n=3 for CD99-S) and were sacrificed on day 19 post
transplantation. Mice engrafted with CD99-L cells had
smaller spleens than EV mice (0.048g vs. 0.11g, P=0.004)
and CD99-S mice (0.048g vs. 0.10g, P=0.026). (Figure 6E and
F). CD99-L mice had significantly less engraftment than the
EV mice in the BM (25.38% vs. 59.57%, P=0.003) (Figure
6G), PB (15.03% vs. 50.5%, P=0.0051) (Figure 6H), and liver
(21.6% vs. 44.03%, P=0.011) (Online Supplementary Figures
S10C and S11). No difference in engraftment was seen in
spleen (Online Supplementary Figure S10D). Additionally, to
determine whether mice engrafted with CD99-L cells
developed deadly leukemia, two CD99-L engrafted mice
were sacrificed only when mice appeared sick (days 29 and
44). We observed PB engraftment in both mice and in the
BM of one mouse (Online Supplementary Figure S10).
Hematoxylin & Eosin staining of the liver, spleen and ster-
num showed that EV and CD99-S tissues presented a high-
er percentage of infiltrated blasts compared with the CD99-
L mice tissues (Online Supplementary Figure S10). We also
found higher CD45 immunostaining (CD99-L vs. EV,
P=0.004; CD99-L vs. CD99-S, P=0.13) and Ki67 staining
(CD99-L vs. EV, P=0.0002; CD99-L vs. CD99-S, P=0.17) in
V.P. Vaikari et al.
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Figure 5. Functional analysis of
CD99-L and CD99-S isoform over-
expression in vitro. (A)
Representative images for aggre-
gation assay of THP-1 EV, CD99-L
and CD99-S cells taken 6 hours (h)
after seeding. (B) Migration of EV,
CD99-L, and CD99-S in THP-1,
U937, and MOLM 13 cells ana-
lyzed by measuring cells that
migrated towards SDF-1α using
transwell plates (n=3). (C)
Representative images for migra-
tion assay of EV, CD99-L, and
CD99-S in THP-1, U937, and
MOLM-13 cells. (D) CD11b analy-
sis of EV, CD99-L, and CD99-S
cells measured by flow cytometry
in THP-1, U937, and MOLM-13
cells (n=4). (**** P<0.0001; ***
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Figure 6. Effect of CD99-L and CD99-S isoform overexpression in acute myeloid leukemia (AML) murine models. 2.5x106 THP-1 EV (n=6), CD99-L (n=6), or CD99-
S (n=3) cells were implanted in mice and sacrificed when sick (days 30-32 post implantation). (A and B) Spleen weight and images of blank, EV, CD99-L, and CD99-
S mice at time of sacrifice. (C and D) Bone marrow (BM) and peripheral blood (PB) engraftment of THP-1 cells in EV, CD99-L and CD99-S mice determined by quan-
titative analysis of CD45+ cells through flow cytometry. 2.5x106 MOLM-13 EV (n=6), CD99-L (n=6), or CD99-S (n=3) cells were implanted in mice and sacrificed when
mice were sick. (E and F) Spleen weight and images of blank, EV, CD99-L, and CD99-S mice at  time of sacrifice. (G and H) BM and PB engraftment of MOLM-13
cells in EV, CD99-L, and CD99-S mice determined by quantitative analysis of CD45+ cells through flow cytometry. (I-K) Representative images of immunostaining for
CD45 and Ki67 on collected tissues of (I) spleen, (J) liver, and (K) sternum. (L and M) Quantitative analysis of Ki67 and CD45 cells in the liver tissues of mice engraft-
ed with MOLM-13 EV, CD99-L, and CD99-S cells quantified using ImageJ. 1x106 primary AML cells over-expressing EV (n=3) or CD99-L (n=3) cells were engrafted in
mice and sacrificed when mice were sick (day 19 post-cell transplantation).  (N and O) Spleen weight and images of EV and CD99-L mice at the time of sacrifice (4-
months post transplantation). (P and Q) BM and PB engraftment of primary AML cells in EV and CD99-L mice determined by quantitative analysis of CD45+ cells by
flow cytometry. (****P<0.0001; ***P<0.001; **P<0.01; *P<0.05).
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EV and CD99-S tissues compared with CD99-L tissues,
confirming a decrease in leukemia engraftment in mice
with CD99-L cells (Figure 6I-M).
In a primary blast murine model, we engrafted primary
AML samples (AML-4) transduced with CD99-L (n=3) or
EV (n=3) in sub-lethally irradiated mice. Mice were sac-
rificed four months post engraftment (Figure 6N-O).
CD99-L mice had less BM engraftment, though this was
not significant compared with the EV mice (1.52 vs.
4.76%, P=0.1) (Figure 6P), and a significant decrease in
hCD45+ cells in PB (7.5% vs. 26.9 %, P=0.005) (Figure 6Q
and Online Supplementary Figures S10 and S12). 
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Figure 7. Effect of CD99 mAB on acute myeloid leukemia (AML) cells. (A) Cell viability of AML blasts treated with 20µg/mL of mAbCD99 for 48 hours (h) and meas-
ured using trypan-blue (n=7). (B) Total number of colonies  comparison between AML blasts treated with mAb CD99 and control blasts (n=6). (C) Viability of THP-1,
MOLM-13 and healthy donor peripheral blood mononuclear cells (PBMC) treated with 5µg/mL of mAbCD99 for 48 h and measured using alamar blue. (D and E)
Apoptosis measured in THP-1 and MOLM-13 cells treated with mAbCD99 for 72 h and stained with Annexin V for flow cytometry analysis. (F and G) Quantitative analy-
sis and representative images of migration of THP-1, MOLM-13 and PBMC treated with mAB CD99 towards SDF-1α performed in a transwell plate. (H) CD11b meas-
ured by flow cytometry in THP-1 cells 72 h post treatment with 2.5 µg/mL of mAB CD99. (I) Representative images for Wright-Giemsa staining of THP-1 cells treated






CD99 monoclonal antibody treatment exhibits
antileukemia activity in acute myeloid leukemia cells
Acute myeloid leukemia patient blasts (n=7) incubated
with monoclonal CD99 antibody (mAbCD99: 20 mg/mL)
showed a significant decrease in cell viability (48 h:
0.5±0.02-fold, P<0.0001) (Figure 7A). Treatment with
mAbCD99 caused a decrease in colony formation in 3 of
6 patient samples: AML-2 (0.5-fold, P=0.02), AML-6 (0.65-
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Figure 8. Effect of CD99 on ERK and SRC signaling pathways in acute myeloid leukemia (AML) cells. (A) Western blot analysis of SRC and ERK signaling pathways
in THP-1 cells transduced with EV, CD99-L, and CD99-S lenti-virus for 72 hours (h). (B) Western blot analysis of SRC and ERK signaling pathways in THP-1 cells trans-
fected with siCD99 for 48 h. (C)  MDM2 western blot analysis in THP-1 cells transduced with EV, CD99-L, and CD99-S lentivirus. (D) MDM2 analysis performed by
western blot in THP-1 cells treated with mAbCD99 for 1, 2, and 9 h. (E) ERK signaling pathway analyzed in THP-1 cells treated with mAbCD99 for 1, 3, and 9 h. (F)
Cyclin D1 mRNA expression measured by taqman assay in THP-1 cells transduced with EV, CD99-L and <CD99-S lentivirus. (G) CCND1 mRNA expression measured
by taqman assay in THP-1 cells transfected with siCD99. (H) Western blot analysis of SRC and ERK signaling pathways in THP-1 stable cells transduced with EV,
CD99-L and CD99-S lentivirus. (I) SRC signaling pathway analyzed in THP-1 cells treated with mAbCD99 for 1 and 9 h. (J) ERK and SRC signaling pathway analyzed





fold, P=0.03), and AML-7 (0.36-fold, P=0.01) (Figure 7B).
Treatment with mAbCD99 (5 mg/mL) caused a 50%
decrease in cell viability at 48 h in THP-1 and MOLM-13
cells but not in healthy donor PBMC (P<0.0001 and
P<0.001, respectively) (Figure 7C). The decrease in viabil-
ity was accompanied by an increase in Annexin-V apopto-
sis stain in THP-1 (7.35-fold, P=0.04) (Figure 7D and E).
Four hours after treatment with mAbCD99 (5 mg/mL) we
found an approximately 70% decrease in cell migration in
both THP-1 and MOLM-13 cells (P=0.01 and P=0.004,
respectively) (Figure 7F and G). Treatment of THP-1 cells
with mAbCD99 triggered an increase in CD11b+ popula-
tion, indicative of myeloid differentiation (2.79-fold,
P=0.04) (Figure 7H). Consistently, Wright-Giemsa stain
revealed that mAbCD99 (2.5 mg/mL) induced differentia-
tion with morphology resembling more mature cell fates
(Figure 7I).
CD99 modulates ERK and SRC signaling pathways in
acute myeloid leukemia cells
Because the initial enhanced proliferation of CD99-L
expressing cells was serum stimulated and transient, we
speculated that growth factor-induced signaling pathways
are affected by CD99. In EWS and osteosarcoma, CD99
was found to modulate ERK pathways.35,36 Thus, we
examined the effect of ectopic expression of CD99 iso-
forms on AKT and ERK kinase activity. We also assessed
changes in SRC signaling, previously shown to be affected
by CD99.17,37 CD99-L induces transient upregulation of P-
ERK, P-AKT and P-SRC compared with CD99-S and EV
expressing cells (Figure 8A and Online Supplementary Figure
S13) measured 72 h post viral transduction. CD99 knock-
down (against both S and L) decreased P-ERK but
increased P-AKT and P-SRC (THP-1 cells express mainly
CD99-S isoform) (Figure 8B). In EWS, treatment with
CD99-antibody induced cell death via rapid decrease of
MDM2 and activation of IGF-1R and ERK signaling.35,36
Thus, we asked whether MDM2 is affected by CD99
expression. CD99-L cells exhibit lower MDM2 protein
levels compared with CD99-S and EV cells (Figure 8C). In
addition, MDM2 is reduced in cells treated with
CD99mAb 2-9 h post treatment (Figure 8D), yet P-ERK
was not changed (Figure 8E and J). Because MDM2 is
known to ubiquitinate IGF-1R, we speculated that CD99-
induced reduction in MDM2 may up-regulate IGF-1R
downstream target genes such as Cyclin D1.38 CCND1
mRNA levels in CD99-L cells were higher than that in
CD99-S (1.75-fold, P=0.02) or EV (2.8-fold, P<0.0001)
(Figure 8F). CD99 knockdown also decreased CCND1
mRNA (P<0.0001) (Figure 8G). We also examined P-ERK
and P-SRC in stable cells maintained in culture for >2
weeks (Figure 8H). Contrary to the early effect, we found
a dramatic decrease in P-SRC in CD99-L cells. Similarly,
cells treated with anti-CD99mAb showed a rapid increase
in P-SRC observed within 1-2 h followed by a decrease in
P-SRC observed 3-9 h post treatment (Figure 8I and J). 
Discussion 
CD99 upregulation has been implicated in several
malignancies and is mostly known for its role in EWS.6,39
Chung et al. have recently shown that CD99+ cells
expressed an antigenic profile that enriches leukemia stem
cells in the majority of human AML. They also demon-
strated anti-leukemia activity of the CD99-antibody both
in cellular and murine models.17 Because AML is a hetero-
geneous disease, it is essential to identify patients with
high CD99 expression that may benefit from treatments
aimed to target this gene. Our analysis revealed an associ-
ation between CD99 overexpression and the presence of
FLT3-ITD. A previous study has shown that
CD123/CD99/CD25(+) cells in a CD34+ cell fraction pre-
dict FLT3-ITD mutations.40 Patients with FLT3-ITD have a
dismal clinical outcome. Whether targeting CD99 in this
patient population provides a therapeutic advantage
remains to be investigated. Despite its upregulation in
AML, high CD99was associated with better outcome. Yet
this association was only observed in CA-AML and was
not significant in multivariate survival analysis. The
inverse correlation between high CD99 and P53 muta-
tions is likely driving its association with better clinical
outcome as P53 mutations are most common in complex
karyotype patients and associated with inferior outcome.41
CD99 is expressed as short and long isoforms with tis-
sue-specific differential expression. However, the different
roles of CD99 isoforms in normal and malignant tissues is
only supported by limited research. Considering the
increased interest in CD99 as a therapeutic target in AML,
investigating the roles of its isoforms in preclinical studies
is essential.18 RNA sequencing data of patients’ samples
revealed that transcripts coding for CD99-S and L iso-
forms are both expressed in AML. We further observed
varying levels of CD99 isoform protein expression in HD
PBMC and AML cell lines. However, the ability of western
blot to compare isoform levels is limited by the antibodies
that are generated against different epitopes. Furthermore,
CD99 is highly glycosylated, which also affects the size of
the protein band. Due to the limited number of cells in our
experiments, we were unable to distinguish CD99 iso-
form protein expression in primary AML blasts. 
The two isoforms have distinct, and maybe opposite,
functions in malignancies. Studies of the ectopic expres-
sion of CD99-L isoform supported an oncosuppressor
function in osteosarcoma.42 Overexpression of CD99-S
isoform, however, resulted in decreased cell aggregation
and increased cell migration in osteosarcoma and prostate
cancer cells.42 In EWS, CD99-S inhibited cell differentia-
tion and contributed to the maintenance of stemness.43
Downregulation of CD99-L transformed B lymphocytes
to Hodgkin and Reed-Sternberg phenotype.44 Our data
suggest that CD99-L cells are more responsive to serum
stimuli with increased DNA synthesis and cell growth;
however, over time, these cells accumulate higher ROS
and DNA damage, resulting in apoptosis. We speculate
that CD99 homotypic interaction is likely driving the later
reduction of cell viability in CD99-L cells. While this phe-
nomenon resembles oncogene-induced senescence,45 only
a slight increase in P16 was observed in CD99-L cells (data
not shown).  
CD99-L consistently delayed disease progression in
AML murine models. Whether CD99 interaction with the
murine microenvironment inhibits cell homing to the BM
is unclear. Yet we observed no change in CXCR4 and
CD49d (VLA-4a) on the surface of CD99-L cells (data not
shown). Mechanistically, CD99-L induced P-SRC and P-
ERK is likely driving the initial increase in cell growth. A
CD99-derived agonist peptide that specifically interacts
with conserved motifs in the CD99 extracellular domain
was previously found to inhibit fibronectin-mediated β1
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integrin activation through the SHP2/ERK/PTPN12/FAK
signaling pathway;37 they also found that ERK is essential
for CD99 homotypic aggregation.46 CD99 homotypic
interactions driving a negative feedback loop or via its sub-
sequent binding with caveolin may explain the later inhi-
bition of ERK and SRC.42 CD99 was found to drive termi-
nal differentiation of osteosarcoma cells via activation of
membrane-bound/cytoplasmic ERK rather than affecting
its nuclear localization.47 Yet, in EWS, CD99 knockdown
led to prolonged nuclear phosphorylation of ERK1/2 and
neural differentiation.48 In addition, CD99mAb was
shown to act as an agonist, and reported similar pheno-
types to those observed in our study.46,49 Both CD99-L
ectopic expression and CD99mAb induced similar cellular
effects, and, likewise, modulated P-SRC. However, further
biochemical studies are required to establish whether
CD99mAb acts as an agonist for CD99 long isoform. 
In summary, our results present unique insights into the
clinical, functional, and mechanistic roles of CD99 iso-
forms in AML. The mechanisms by which CD99 is up-
regulated and those that govern its function in leukemia
initiation remain to be investigated. 
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